December 22, 2021 GlobeNewswire BetterLife’s Wholly-Owned Subsidiary, Altum Pharmaceuticals, Obtains Non-Dilutive Financing Commitment From Strategic Investor! Read More
December 9, 2021 GlobeNewswire BetterLife Obtains Positive TD-0148A Data in Preclinical Models of Depression Read More
December 3, 2021 GlobeNewswire H.C. Wainwright 2nd Annual Psychedelics Conference, BACK TO THE FUTURE! Read More
November 29, 2021 SEC Filings BetterLife Successfully Completes Phase 1 and Initiates Phase 2 Clinical Trials with Interferon Alpha-2b in COVID-19 Patients in Chile Read More
November 29, 2021 GlobeNewswire BetterLife Successfully Completes Phase 1 and Initiates Phase 2 Clinical Trials with Interferon Alpha-2b in COVID-19 Patients in Chile Read More
November 16, 2021 TDM Financial BetterLife Obtains TD-0148A Behavioural Pharmacology Data Confirming its Projected Non-hallucinogenic Property Read More
November 5, 2021 GlobeNewswire Developing Psychedelic Medicine Beyond What We Already Know! Read More
November 4, 2021 GlobeNewswire BetterLife Obtains TD-0148A In Vitro Pharmacology Data Confirming its Activity in Key Receptors Implicated in Depression and Neuropathic Pain Read More
October 25, 2021 Uncategorized BetterLife Pharma: Invitation to the Benzinga Global Small Cap Conference Read More
October 12, 2021 GlobeNewswire Early Results of BetterLife Preclinical Study Show AP-003 (rhIFN⍺2b) Provides Up to 97% Protection in Human Cells Against the Delta Variant of SARS-CoV-2 Read More